ERBB2 and breast carcinoma: The current study will be the first systematic review and cumulative NMA that specifically evaluates the totality of the publicly available evidence on originator trastuzumab as a treatment for HER2+ early breast cancer, and the first NMA that combines RCTs and non-randomized studies of originator trastuzumab compared with alternative treatments.